Lenvatinib can increase the levels of phosphorylated CHK1 (p-CHK1) protein in HCC cells, and when used in combination with the CHK1 inhibitor Prexasertib, it exhibits synergistic anti-tumor effects in both HCC cells and in vivo experiments. Here, CHEK1 is linked to hepatocellular carcinoma.